|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Corautus Genetics |
|---|---|
| Information provided by: | Corautus Genetics |
| ClinicalTrials.gov Identifier: | NCT00090714 |
Purpose
The purpose of this study is to determine the optimum effective dose of recombinant plasmid DNA [pVGI.1(VEGF2)] gene therapy administered using an experimental cardiac direct injection catheter (Stiletto™) system needed to benefit patients with severe Angina Pectoris.
| Condition | Intervention | Phase |
|---|---|---|
|
Angina Pectoris |
Gene Transfer: pVGI.1(VEGF2) |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Show 35 Study Locations
More Information
| Study ID Numbers: | VEGF2-CAD-CL-007, NIH RAC # 0301-567 |
| Study First Received: | September 2, 2004 |
| Last Updated: | April 18, 2006 |
| ClinicalTrials.gov Identifier: | NCT00090714 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
DNA Circular Gene Therapy |
|
Signs and Symptoms Heart Diseases Myocardial Ischemia Vascular Diseases |
Angina Pectoris Pain Cardiovascular Diseases Chest Pain |